These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15170136)

  • 1. High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer.
    Oshita F; Kameda Y; Hamanaka N; Saito H; Yamada K; Noda K; Mitsuda A
    Am J Clin Oncol; 2004 Jun; 27(3):215-9. PubMed ID: 15170136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer.
    Oshita F; Kameda Y; Ikehara M; Tanaka G; Yamada K; Nomura I; Noda K; Shotsu A; Fujita A; Arai H; Ito H; Nakayama H; Mitsuda A
    Anticancer Res; 2002; 22(2B):1065-70. PubMed ID: 12168902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer.
    Oshita F; Ito H; Ikehara M; Ohgane N; Hamanaka N; Nakayama H; Saito H; Yamada K; Noda K; Mitsuda A; Kameda Y
    Am J Clin Oncol; 2004 Aug; 27(4):425-8. PubMed ID: 15289739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome.
    Joseph MG; Banerjee D; Kocha W; Feld R; Stitt LW; Cherian MG
    Cancer; 2001 Aug; 92(4):836-42. PubMed ID: 11550155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
    Micke P; Basrai M; Faldum A; Bittinger F; Rönnstrand L; Blaukat A; Beeh KM; Oesch F; Fischer B; Buhl R; Hengstler JG
    Clin Cancer Res; 2003 Jan; 9(1):188-94. PubMed ID: 12538468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer.
    Chang MH; Lee K; Lee KY; Kim YS; Kim YK; Kang JH
    APMIS; 2012 Jan; 120(1):28-38. PubMed ID: 22151306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis.
    Micke P; Hengstler JG; Ros R; Bittinger F; Metz T; Gebhard S; Beeh KM; Oesch F; Buhl R
    Int J Cancer; 2001 May; 92(4):474-9. PubMed ID: 11304679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas.
    Rodríguez-Salas N; Palacios J; Moreno G; de Castro J; González-Barón M; Gamallo C
    Lung Cancer; 2001 Oct; 34(1):67-74. PubMed ID: 11557115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
    Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
    J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome.
    Gemba K; Ueoka H; Kiura K; Tabata M; Harada M
    Lung Cancer; 2000 Jul; 29(1):23-31. PubMed ID: 10880844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC-MS/MS combined with iTRAQ technology.
    Zhang PF; Zeng GQ; Yi LZ; Liu JP; Wan XX; Qu JQ; Li JH; Li C; Tang CE; Hu R; Ye X; Chen Y; Chen ZC; Xiao ZQ
    Oncol Rep; 2013 Jul; 30(1):341-9. PubMed ID: 23677397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.
    Takayama K; Ogata K; Nakanishi Y; Yatsunami J; Kawasaki M; Hara N
    Cancer J Sci Am; 1996; 2(4):212-6. PubMed ID: 9166534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.
    Paik KH; Park YH; Ryoo BY; Yang SH; Lee JC; Kim CH; Ki SS; Kim JM; Park MJ; Ahn HJ; Choi W; Chung JH
    J Korean Med Sci; 2006 Feb; 21(1):35-9. PubMed ID: 16479062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer.
    Zalcman G; Trédaniel J; Schlichtholz B; Urban T; Milleron B; Lubin R; Meignin V; Couderc LJ; Hirsch A; Soussi T
    Int J Cancer; 2000 Jan; 89(1):81-6. PubMed ID: 10719735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
    Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
    Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.